<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A standard therapeutic regimen of a <z:chebi fb="0" ids="28790">5-HT</z:chebi>₃ receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="50919">antiemetic</z:chebi> agent+<z:chebi fb="0" ids="41879">dexamethasone</z:chebi> was administered as <z:chebi fb="0" ids="50919">antiemetic</z:chebi> therapy for 29 patients who received chemotherapy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in the Department of Surgery at Gunma Saiseikai Maebashi Hospital, from January to March 2010 </plain></SENT>
<SENT sid="1" pm="."><plain>For 13 patients with delayed <z:hpo ids='HP_0002018'>nausea</z:hpo>, the therapy was changed to an aprepitant regimen (aprepitant+5-HT₃ receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="50919">antiemetic</z:chebi> agent+<z:chebi fb="0" ids="41879">dexamethasone</z:chebi>)to evaluate the preventive effect of aprepitant on <z:hpo ids='HP_0011009'>acute</z:hpo> and delayed <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This aprepitant regimen produced a significant improvement in the primary endpoint, based on a complete response (CR) of no <z:hpo ids='HP_0002013'>vomiting</z:hpo> and no rescue treatment throughout the administration period, and in the secondary endpoint of CR in the delayed phase, with no delayed <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, a tendency for improvement was found in other secondary endpoints: complete protection (CP) based on no <z:hpo ids='HP_0002013'>vomiting</z:hpo>, no rescue treatment, and no significant <z:hpo ids='HP_0002018'>nausea</z:hpo> throughout the observation period; no <z:hpo ids='HP_0002013'>vomiting</z:hpo>; and no significant <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>These findings suggest that using aprepitant as an <z:chebi fb="0" ids="50919">antiemetic</z:chebi> therapy during chemotherapy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> may be effective for patients with <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo> that are intractable to standard therapeutic regimens </plain></SENT>
</text></document>